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Background: The purpose of the study was to compare the safety of artemether-lumefantrine (AL) with other
artemisinin-based combinations in children.
Methods: A search of EMBASE (from 1974 to April 2013), MEDLINE (from 1946 to April 2013) and the Cochrane
library of registered controlled trials for randomized controlled trials (RCTs) which compared AL with other
artemisinin-based combinations was done. Only studies involving children ≤ 17 years old in which safety of AL was
an outcome measure were included.
Results: Four thousand, seven hundred and twenty six adverse events (AEs) were recorded in 6,000 patients
receiving AL. Common AEs (≥1/100 and <1/10) included: coryza, vomiting, anaemia, diarrhoea, vomiting and
abdominal pain; while cough was the only very commonly reported AE (≥1/10). AL-treated children have a higher
risk of body weakness (64.9%) than those on artesunate-mefloquine (58.2%) (p = 0.004, RR: 1.12 95% CI: 1.04-1.21).
The risk of vomiting was significantly lower in patients on AL (8.8%) than artesunate-amodiaquine (10.6%) (p = 0.002,
RR: 0.76, 95% CI: 0.63-0.90). Similarly, children on AL had a lower risk of vomiting (1.2%) than chlorproguanil-dapsone-
artesunate (ACD) treated children (5.2%) (p = 0.002, RR: 0.63, 95% CI: 0.47-0.85). The risk of serious adverse events was
significantly lower for AL (1.3%) than ACD (5.2%) (p = 0.002, RR: 0.45, 95% CI: 0.27-0.74).
Conclusion: Artemether-lumefantrine combination is as safe as ASAQ and DP for use in children. Common adverse
events are cough and gastrointestinal symptoms. More studies comparing AL with artesunate-mefloquine and
artesunate-azithromycin are needed to determine the comparative safety of these drugs.
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Malaria, caused by Plasmodium falciparum, is an import-
ant public health problem in Africa. It accounts for an esti-
mated 660,000 deaths in 2010, mostly among African
children [1]. Due to the increasing resistance of malaria
parasite to older anti-malarial drugs, such as chloroquine
and sulphadoxine-pyrimethamine, artemisinin-based com-
bination therapy (ACT) has been recommended by the
World Health Organization (WHO) [2]. This approach
involves the combination of artemisinin, or one of its deriv-
atives, with other anti-malarials, such as amodiaquine,* Correspondence: mzxoe@nottingham.ac.uk
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distribution, and reproduction in any mediumlumefantrine or sulphadoxine-pyrimethamine. Several stud-
ies have demonstrated the efficacy of ACT for malaria
treatment [3]. A combination therapy explores the syner-
gistic or additive effect of two or more drugs with different
mechanisms of action to improve the therapeutic efficacy,
increase the therapeutic drug life and delay the develop-
ment of resistance to each of the component drugs in the
combination [4].
Artemether-lumefantrine (AL) is one of the most com-
monly used combinations in sub-Saharan Africa. It is
the first-line treatment for uncomplicated malaria in sev-
eral countries. It is available in oral form as a fixed dose
combination (20 mg artemether and 120 mg lumefan-
trine) and given as a six dose regimen for the treatment
of uncomplicated malaria. Artemether has a short half-ed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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about 5 days [4-6]. Artemether rapidly and extensively
reduces parasite biomass, while lumefantrine clears the
residual parasites from the body [7].
Although AL is widely prescribed, several other com-
binations are increasingly being explored and used but
data are lacking on their safety. Most of the previous
studies have compared the efficacies of AL and other
artemisinin-based combinations, but little or no atten-
tion has been given to their safety. AL has been shown
to be relatively safe when compared with other antima-
larials such as quinine, sulphadoxine-pyrimethamine and
chloroquine [8]. Adverse effects, such as headache, dizzi-
ness, abdominal pain anorexia, anaemia, arthralgia, my-
algia, diarrhoea, vomiting, nausea, weakness and rash,
have been documented [9,10]. Given the wide range of
ACT available for malaria treatment and their potential
adverse effects, it is imperative to compare their safety
profiles. This systematic was, therefore, performed to
compare the safety profiles of AL with other ACT in
children.
Methods
Search strategy
Embase (from January 1974 to April 2013), Medline
(from January 1946 to April 2013) and the Cochrane li-
brary of registered controlled trials for randomized con-
trolled trials (RCTs) were searched for RCTs comparing
AL with other artemisinin-based combinations. Search
terms such as artemisinin or artemether or artesunate or
dihydroartemisinin were combined with lumefantrine or
amodiaquine or sulphadoxine-pyrimethamine or meflo-
quine or chloproguanil or dapsone or piperaquine or
azithromycin. Only studies involving children ≤ 17 years
old in which safety of AL was an outcome measure were
included. There was no restriction on the language of
publication.
Data extraction
Two reviewers extracted data from the included studies
onto data extraction form.
Data extracted from each study included: the com-
parator drug, the number of participants in each arm of
the study, year of the study, duration of follow-up, age of
the participants, dose of drugs administered, the number
of deaths recorded, the number of participants who
withdrew from the study, and the adverse event (AE)
data for both AL and the comparator drugs. All data
were compared and agreed to by both reviewers.
Data quality assessment
To minimize the risk of bias, the quality of included ran-
domized controlled trials was assessed using the
Cochrane collaboration’s tool for assessing risk of bias inrandomized trials [11]; quality of reported safety studies
was also assessed using the modified CONSORT check-
list for reporting of harmful effects [12]. Articles with
modified CONSORT score of ≥6 out of 9 criteria were
considered to have provided good quality safety report-
ing. All RCTs were included for meta-analyses. Highly
biased and poor quality studies were subsequently ex-
cluded in sensitivity analysis. Two reviewers independ-
ently scored and agreed on articles included. Kappa
statistic was used to determine the level of agreements
on the quality assessment between the two reviewers (k
= 0.92) [13].
Data collection and statistical analysis
The relevant data were extracted onto an excel spread
sheet. All studies were grouped based on the comparator
drug and AEs in each pool were aggregated for meta-
analysis. The adverse event profile of AL was used as the
reference against which other artemisinin-based combi-
nations were compared. Meta-analysis was done using
Revman version 5. Relative risk was calculated for all
AEs reported in more than one study. A relative risk
(RR) >1 indicates a higher risk of AE in AL relative to
the comparator. The pooled RR was calculated using the
fixed effect model for homogenous data (I2 ≤50% or
Chi2 p ≥ 0.05) and random effect model for heteroge-
neous data (I2 > 50% or Chi2 p < 0.05) as suggested by
DerSimonian and Laird [14].
Results
Safety information was extracted from 27 RCTs (Figure 1),
which met our inclusion criteria [15-41]. After risk of bias
assessment, 7 studies were of high risk [23-25,34-37]. The
age of the patients ranged between six weeks and 18 years
(Table 1). In all studies, a six-dose regimen of AL (20 mg
artemether and 120 mg lumefantrine) was administered over
three days. The total number of children administered ACT
was 15,119. Four thousand, seven hundred and twenty six
AEs were recorded in 6,000 patients receiving AL. All but
one of the RCTs, were conducted in Africa (Nigeria, Ghana,
Benin, Uganda, Kenya, Tanzania, Ivory Coast, Burkina
Faso, Senegal and Gabon). The only non-African country
was Paupa New Guinea. Common AEs (≥1/100 and
<1/10) among patients receiving AL included: coryza,
vomiting, anaemia, diarrhoea, vomiting and abdominal
pain; while cough was the only very commonly reported
AE (≥1/10) (Table 2). The respiratory and gastrointes-
tinal tracts were the most commonly affected systems
constituting 35% and 33% respectively, of all the re-
ported AEs in AL treated children. Other artemisinin
based combinations compared with AL were: artesunate-
amodiaquine (ASAQ), dihydroartemisinin-piperaquine (DP),
chlorproguanil-dapsone-artesunate (ACD), artesunate-
mefloquine (AM) and artesunate-azithromycin (AAZ).
Figure 1 Flow chart for studies included in the systematic review.
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Eleven studies involving 5958 children compared AL
with DP [15-25]. There were three cases of death in each
of the drug groups; none was related to the drugs. The
risk of serious adverse events (SAEs) was lower with AL
(0.5%) than DP (1.2%), although this difference was not
statistically significant (p = 0.09, RR 0.62 95%CI 0.36-
1.07). In one of the studies, two unnamed SAEs in AL
arm and four in DP group were considered to have
causal relationship with the drugs [20]. In another study,
one patient receiving AL developed severe anaemia,
which was considered to be possibly associated with the
drug [22]. In Table 3, the children receiving AL had a
minimally higher risk of abdominal pain (10.9%) than
those receiving DP (10.4%) (p = 0.09, RR 1.31, 95% CI
0.99-1.73). After a study with a high risk of bias [24] was
excluded in a sensitivity analysis, the risk of abdominal
pain was statistically significant (p = 0.04). Table 3 shows
that the risks of other common adverse events such as
pruritus, diarrhoea, cough, vomiting and weakness of the
body were not significantly different between the two
drug groups (p > 0.05).
AL and ASAQ
Thirteen studies involving 6018 children comparing AL
with ASAQ were included and analysed [20,26-37]. The
risk of SAEs was not significantly different for both
treatment groups (p = 0.07 RR: 0.54, 95% CI: 0.27-1.05).Table 1 Characteristics of treatment groups
Drugs AL and DP AL an
Age range(months) 6-168 6-180
Median (IQR) duration of follow-up (days) 35(22.8-51.8) 35(12
Number of studies 11 3
Number of patients in AL arm 3343 1861
Number in comparator arm 4284 1505The percentage risks of SAEs in the AL and ASAQ
groups were 0.8% and 1.5% respectively. Most of the re-
ported SAEs were judged to be unlikely related to the
medications studied. However in one study [20], four un-
named SAEs in patients receiving ASAQ and two in those
receiving AL were considered to be drug related. There
were only three documented cases of mortality, two in the
AL group and one in the ASAQ group. None of the deaths
was treatment related. Table 3 shows that the risk of
vomiting was significantly lower in patients on AL (8.8%)
than ASAQ (10.6%) (p = 0.002, RR: 0.80, 95% CI: 0.66-
0.97). After excluding one poor quality RCT [34] in a sen-
sitivity analysis, the risk of vomiting remained statistically
significant (p=0.002). The risk of other AEs, such as weak-
ness, pruritus, anaemia, diarrhoea, abdominal pain, an-
orexia and cough, was not statistically significant (p > 0.05)
with or without biased RCTs.
AL and ACD
Three studies comparing AL with ACD involving 3366
children were included in this review [20,26,38]. Two of
these studies compared more than one artemisinin-
based combination. All included RCTs were rated as low
risk. The overall risk of SAE was significantly lower for
AL (1.3%) than ACD (5.2%) (p = 0.002, RR: 0.45, 95% CI:
0.27-0.74). Forty-six (73%) and three (20%) of the SAEs
in the ACD and AL groups, respectively, were due to
oxidative haemolysis. Majority of the haemolytic AEs ind ACD AL and ASAQ AL and AM AL and AAZ
1.5-120 6-216 6-59
.3-42) 28(21-42) 28 42
13 2 1
3054 239 132
2964 237 129
Table 2 Organ-system classification and risk of adverse events in AL treated children
System organ class Adverse event Number of adverse events Risk (per 1000 patients)
Gastrointestinal disorders Abdominal pain 187 31.2
Anorexia 442 73.7
Diarrhoea 371 61.8
Nausea/vomiting 471 78.5
Others 109 18.2
General disorders Weakness 372 62
Pyrexia 372 62
Mouth ulcer 13 2.2
Salivation 7 1.2
Unable to suck 5 0.8
Body pain 10 1.7
Hypersensitivity reaction 3 0.5
Puffy face 1 0.2
Respiratory disorders Cough 1152 192
Coryza 449 74.8
Dyspnoea 4 0.7
Others 55 9.2
Central Nervous system disorders Headache 228 38
Dizziness 18 3
Insomnia 23 3.8
Convulsion 3 0.5
Nystagmus 1 0.2
Skin and appendages disorders Rash 55 9.2
Pruritus 90 15
Urticaria 2 0.3
Others 35 5.8
Haematological disorders Anaemia 157 26.2
Haemolysis 3 0.5
Thrombocytopaenia 9 1.5
Neutropenia 42 7
Liver and biliary system disorders Jaundice 3 0.5
Elevated ALT 23 3.8
Hepatomegaly 4 0.7
Musculo-skeletal system disorders Joint pain 1 0.2
Cardiovascular disorders Palpitation 6 1
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dren. All the three cases of haemolysis in the AL group
were in G6PD normal children. There were three and
four cases of deaths, respectively, for AL and ACD; none
was considered treatment related. In Table 3, the risk of
vomiting was significantly lower for AL (1.2%) than
ACD (5.2%) (p = 0.002, RR: 0.63, 95% CI: 0.47-0.85). No
other adverse event showed a statistically significant dif-
ference between both drugs.AL and AM
Two studies involving 476 children compared AL with AM
[39,40]. None of the studies reported death or SAEs for
both drugs. In Table 3, pooled analyses of both RCTs
showed a statistically significantly higher risk of weakness
for AL treated children (64.6%) than AM (58.2%) (p = 0.004,
RR: 1.12 95% CI: 1.04-1.21). Vomiting and abdominal pain,
which were the other two AEs reported in both studies,
were not significantly different in both treatment groups.
Table 3 Relative risk of AEs between AL and other artemisinin-based combinations
Relative risk of AEs between AL and DP
Adverse event Risk AL (%) Risk comparator (%) Relative risk (95% CI) P value (*significant) References
Vomiting 10.3 9.7 0.99[0.86-1.13] 0.85 15-24
ǂAnaemia 3.7 10.1 0.45[0.20-1.02] 0.05 18, 20
Abdominal pain 10.9 10.4 1.31[0.99-1.73] 0.06 17, 19, 21, 24
Diarrhoea 13.3 12.6 1.03[0.89-1.20] 0.65 15-18, 20-24
Pruritus 5.8 4.5 1.28[0.81-2.02] 0.30 17, 19, 21, 24
Weakness 16.5 13.3 1.14[0.94-1.39] 0.19 15, 17, 19, 21, 24
Cough 39.8 39.2 0.99[0.92-1.05] 0.65 15, 17-19, 20-22, 24
Anorexia 12.3 11.0 1.07[0.93-1.24] 0.38 15, 17, 19-22
SAE 0.5 1.2 0.62[0.36-1.07] 0.09 15-22
Relative risk of AEs between AL and ASAQ
Abdominal pain 14.5 14.3 0.81[0.46-1.40] 0.45 26, 28, 29, 31-34
Pruritus 8.4 9.5 0.78[0.54-1.11] 0.17 26, 28, 31, 34
Anorexia 14.3 17.6 0.88[0.76-1.03] 0.11 20, 26, 29, 31
ǂAnaemia 8.9 19.1 0.61[0.19-1.90 0.39 20, 30, 31, 33
Headache 13.5 7.9 1.29[0.89-1.87] 0.17 29, 32, 34
Vomiting 8.8 10.6 0.80[0.66-0.97] *0.02 20, 26, 28-31, 33, 34
Weakness 12.8 13.4 0.84[0.63-1.13] 0.25 28, 29, 31, 34
Diarrhoea 12.0 10.4 1.09[0.89-1.32] 0.41 20, 27, 32, 34
Cough 31.4 31.2 1.01[0.91-1.12] 0.84 20, 27, 30, 32, 33
SAE 0.8 1.5 0.54[0.27-1.05] 0.07 20, 30-32
Relative risk of AEs between AL and ACD
ǂAnaemia 2.8 7.2 0.35[0.09-1.43] 0.15 26, 38
Anorexia 11.8 17.8 0.80[0.63-1.00] 0.05 20, 26
Cough 29.2 23.0 1.13[0.96-1.34] 0.15 20, 26
Diarrhoea 6.0 8.6 1.28[0.96-1.73] 0.11 20, 26
Vomiting 1.2 5.2 0.63[0.47-0.85] *0.002 20, 26, 38
SAE 1.3 5.2 0.45[0.27-0.74] *0.002 26, 38
Relative risk of AEs between AL and AM
Weakness 64.9 58.2 1.12[1.04-1.21] *0.004 39, 40
Abdominal pain 1.7 3.8 0.44[0.14-1.41] 0.17 39, 40
Vomiting 21.3 22.8 0.75[0.27-2.05] 0.57 39, 40
ǂ Random effect model.
* (<0.05) statistically significant’.
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Only one RCT involving 261 patients compared the
safety of AAZ with AL in paediatric patients [41]. This
study showed that children taking AAZ have a signifi-
cantly higher risk of vomiting than those on AL (p =
0.02). The risk of other AEs such as: dizziness, convul-
sion, respiratory and dermatological events were not sig-
nificantly different in both treatment groups.
Discussion
This review identified cough as the most common adverse
event in children receiving AL (Table 2). Other commonadverse events are: abdominal pain, vomiting, anaemia,
headache and diarrhoea. These findings have also been re-
ported by other authors [9,42]. Many of the AEs were ad-
judged to be symptoms of malaria or signs of a progression
of the disease. Generally, AL was well tolerated with only a
few SAEs recorded. Only two unnamed SAEs were consid-
ered to be related to AL treatment. AL treated patients
showed a significantly lower risk of vomiting compared
with ASAQ, ACD and AAZ. A higher risk of weakness was
observed in AL treated children compared with AM.
Due to increased risk of haemolysis, the clinical devel-
opment of ACD, which is a very effective anti-malarial
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RCT by Premji et al. [38] has demonstrated a higher in-
cidence of haemolysis in children receiving ACD than
AL. Given the high prevalence of glucose 6-phosphate
dehydrogenase (G6PD) deficiency (up to 30%) in sub-
Saharan Africa [44], and the fact that G6PD deficient
children are prone to the haemolytic effect of the oxi-
dant metabolite of dapsone [45], halting the develop-
ment of ACD for malaria treatment in Africa was
justified. Malderen et al. [46] showed that G6PD defi-
cient children treated with ACD have a higher, but non-
statistically significant risk of having haemolysis and a
>2 g/dl drop in their haematocrit, than non-deficient pa-
tients. Although ACD development has been stopped, it
may still be relevant in the future fight against malaria.
If such time ever comes, treatment would have to be in-
dividualized, with rapid test of G6PD status done before
ACD prescription. Such tests have been approved by the
US Food and Drug Administration for warfarin therapy
and colon cancer treatment [47,48].
Although mefloquine is associated with neuropsychi-
atric symptoms such as nightmares, hallucinations and
anxiety [49-51], none was recorded in the two RCTs in-
volving AM in this review. The small number of patients
involved in both studies may not be adequately powered
to detect this event. Gastrointestinal events were the
most common adverse events in patients on AM. This is
similar to the report from a study in Nigeria [52]. None
of the gastrointestinal events however showed a signifi-
cant difference between the patients on AM and AL.
Treatment with AL, more than AM, significantly in-
creased the risk of weakness of the body.
Some of the meta-analyses were limited by the relatively
small number of patients in the comparator groups. There-
fore, caution is required when extrapolating the results to
the general population. Besides, such small sample size
may not be sufficiently powered to detect rare events. Sev-
eral of the RCTs reported adverse events rather than ad-
verse reactions of the antimalarial drugs. This made it
impossible to determine the causal relationship between
the antimalarial drugs and the AEs. It was, therefore, diffi-
cult to determine whether an AE is symptomatic of the dis-
ease or drug related. In some other studies, safety
reporting was either selective or inadequate, with some au-
thors failing to indicate the severity of AEs. Some of these
limitations have been identified in studies evaluating the
quality of safety reporting in RCTs [12,53].
Conclusion
Artemether-lumefantrine combination is as safe as
ASAQ and DP for use in children. Common adverse
events are cough and gastrointestinal symptoms. Haem-
olysis in G6PD deficient children makes the use of ACD
undesirable. The few numbers of studies comparing ALwith AM and AAZ would not enable us to make a firm
conclusion on their comparative safety; therefore, more
studies are needed to determine the comparative safety
of AL with AM and AAZ.
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